Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) EBT (2021 - 2025)

Rxo (RXO) has disclosed EBT for 5 consecutive years, with -$51.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 54.55% year-over-year to -$51.0 million, compared with a TTM value of -$115.0 million through Dec 2025, up 62.17%, and an annual FY2025 reading of -$115.0 million, up 62.17% over the prior year.
  • EBT was -$51.0 million for Q4 2025 at Rxo, down from -$15.0 million in the prior quarter.
  • Across five years, EBT topped out at $59.0 million in Q2 2022 and bottomed at -$242.0 million in Q3 2024.
  • Average EBT over 5 years is -$14.2 million, with a median of -$6.0 million recorded in 2022.
  • The sharpest move saw EBT soared 166.67% in 2023, then tumbled 7966.67% in 2024.
  • Year by year, EBT stood at $55.0 million in 2021, then plummeted by 110.91% to -$6.0 million in 2022, then skyrocketed by 166.67% to $4.0 million in 2023, then tumbled by 925.0% to -$33.0 million in 2024, then plummeted by 54.55% to -$51.0 million in 2025.
  • Business Quant data shows EBT for RXO at -$51.0 million in Q4 2025, -$15.0 million in Q3 2025, and -$10.0 million in Q2 2025.